Mostrar el registro sencillo del ítem
dc.contributor.author | Ruiz-Burga, Elisa | |
dc.contributor.author | Tariq, Shema | |
dc.contributor.author | Touloumi, Giota | |
dc.contributor.author | Gill, John | |
dc.contributor.author | Nicholls, Emily Jay | |
dc.contributor.author | Sabin, Caroline | |
dc.contributor.author | Mussini, Cristina | |
dc.contributor.author | Meyer, Laurence | |
dc.contributor.author | Volny Anne, Alain | |
dc.contributor.author | Carlander, Christina | |
dc.contributor.author | Grabar, Sophie | |
dc.contributor.author | Jarrin-Vera, Inmaculada | |
dc.contributor.author | Van der Valk, Marc | |
dc.contributor.author | Wittkop, Linda | |
dc.contributor.author | Spire, Bruno | |
dc.contributor.author | Pantazis, Nikos | |
dc.contributor.author | Burns, Fiona M | |
dc.contributor.author | Porter, Kholoud | |
dc.contributor.author | CASCADE Collaboration | |
dc.date.accessioned | 2023-09-20T13:23:41Z | |
dc.date.available | 2023-09-20T13:23:41Z | |
dc.date.issued | 2023-05-11 | |
dc.identifier.citation | BMJ Open. 2023 May 11;13(5):e070837. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16480 | |
dc.description.abstract | Introduction: Despite the availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), 21 793 people were newly diagnosed with HIV in Europe in 2019. The Concerted action on seroconversion to AIDS and death in Europe study aims to understand current drivers of the HIV epidemic; factors associated with access to, and uptake of prevention methods and ART initiation; and the experiences, needs and outcomes of people with recently acquired HIV. Methods and analysis: This longitudinal observational study is recruiting participants aged ≥16 years with documented laboratory evidence of HIV seroconversion from clinics in Canada and six European countries. We will analyse data from medical records, self-administered questionnaires, semistructured interviews and participatory photography. We will assess temporal trends in transmitted drug resistance and viral subtype and examine outcomes following early ART initiation. We will investigate patient-reported outcomes, well-being, and experiences of, knowledge of, and attitudes to HIV preventions, including PrEP. We will analyse qualitative data thematically and triangulate quantitative and qualitative findings. As patient public involvement is central to this work, we have convened a community advisory board (CAB) comprising people living with HIV. Ethics and dissemination: All respective research ethics committees have approval for data to contribute to international collaborations. Written informed consent is required to take part. A dissemination strategy will be developed in collaboration with CAB and the scientific committee. It will include peer-reviewed publications, conference presentations and accessible summaries of findings on the study's website, social media and via community organisations. | es_ES |
dc.description.sponsorship | This research is funded by ViiV Healthcare UK (award/grant number N/A), Janssen Pharmaceutica NV (award/grant number N/A) and Merck Sharp & Dohme (award/grant number N/A). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMJ Publishing Group | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Acquired Immunodeficiency Syndrome | es_ES |
dc.subject.mesh | Pre-Exposure Prophylaxis | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Canada | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.subject.mesh | Patient Reported Outcome Measures | es_ES |
dc.subject.mesh | Observational Studies as Topic | es_ES |
dc.subject.mesh | Multicenter Studies as Topic | es_ES |
dc.title | CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución-NoComercial 4.0 Internacional | * |
dc.identifier.pubmedID | 37169505 | es_ES |
dc.format.volume | 13 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | e070837 | es_ES |
dc.identifier.doi | 10.1136/bmjopen-2022-070837 | es_ES |
dc.contributor.funder | ViiV Healthcare (United Kingdom) | es_ES |
dc.contributor.funder | Janssen Cilag | es_ES |
dc.contributor.funder | Merck, Sharp & Dohme | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2044-6055 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1136/bmjopen-2022-070837 | es_ES |
dc.identifier.journal | BMJ open | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |